- History Lesson: FDA BA/BE guidance jag009 2012-04-18 17:26
- History Lesson: FDA BA/BE guidance jag009 2012-04-19 19:39
- History Lesson: FDA BA/BE guidance drgunasakaran1 2012-05-01 13:23
- History Lesson: FDA BA/BE guidance jag009 2012-04-19 19:39
- power calculation for partial /full replicate study designs balakotu 2012-04-02 15:06
- Useless power Helmut 2012-04-02 16:19
- Useless power balakotu 2012-04-17 06:11
- Useless power: over & over again Helmut 2012-04-25 16:32
- Useless power: over & over again lindseyk 2012-04-27 16:25
- What for? Helmut 2012-04-28 03:12
- Useless power: over & over again lindseyk 2012-04-27 16:25
- Useless power: over & over again Helmut 2012-04-25 16:32
- Useless power balakotu 2012-04-17 06:11
- Useless power Helmut 2012-04-02 16:19
- phenytoin sodium BE study jagankm 2012-04-24 11:54
- phenytoin sodium BE study Dr_Dan 2012-04-25 12:25
- phenytoin sodium BE study jagankm 2012-04-26 06:17
- phenytoin sodium BE study Dr_Dan 2012-04-26 15:54
- phenytoin sodium BE study jagankm 2012-04-26 06:17
- phenytoin sodium BE study Dr_Dan 2012-04-25 12:25
- Bioequivalence for Levothyroxine Karmegams 2012-04-06 08:02
- Bioequivalence for Levothyroxine drgunasakaran1 2012-04-21 07:58
- Bioequivalence for Levothyroxine Karmegams 2012-04-24 07:51
- Bioequivalence for Levothyroxine drgunasakaran1 2012-04-21 07:58
- BE question: Immedidate Release Tablet for FDA jag009 2012-04-20 22:28
- BE question: Immedidate Release Tablet for FDA drgunasakaran1 2012-04-21 07:46
- BE question: Immedidate Release Tablet for FDA jag009 2012-04-23 15:59
- BE question: Immedidate Release Tablet for FDA drgunasakaran1 2012-04-21 07:46
- In vitro Bioequivalence GSTATS 2011-06-07 18:45
- In vitro Bioequivalence Tushar.g 2012-04-23 07:49
- FDA Guidance for Relative potency within 5% jag009 2012-04-18 21:56
- FDA Guidance for Relative potency within 5% suds4u 2012-04-20 11:58
- FDA Guidance for Relative potency within 5% jag009 2012-04-20 21:33
- FDA Guidance for Relative potency within 5% suds4u 2012-04-20 11:58
- FDA: Biowaiver for other strengths jag009 2012-04-17 19:55
- FDA: Biowaiver for other strengths Dr_Dan 2012-04-19 16:32
- Stability of OTC drugs vinay_vk 2012-04-09 14:11
- Incorporation of Dose in statistical Model pash413 2012-04-06 14:56
- Incorporation of Dose in statistical Model ElMaestro 2012-04-07 13:07
- Line extension case study lukamar 2012-04-03 13:55
- Primary and secondary parameters for SS study for EU ratnakar1811 2012-03-19 12:49
- MR MD studies (EMA) Helmut 2012-03-19 14:18
- Non-superiority Jaime_R 2012-03-19 16:26
- Non-superiority Helmut 2012-03-19 16:59
- 'Non-superiority' - sample size d_labes 2012-03-20 15:48
- To err is Julious d_labes 2012-03-22 10:20
- PowerTOST 0.9-6 on CRAN Helmut 2012-03-30 14:13
- Non-superiority Helmut 2012-03-19 16:59
- Non-superiority Jaime_R 2012-03-19 16:26
- MR MD studies (EMA) Helmut 2012-03-19 14:18
- Drop out handling in Europe Submission Study pash413 2012-03-28 16:04
- Tmax, drop-outs (EMA) Helmut 2012-03-28 16:27
- Tmax, drop-outs (EMA) pash413 2012-03-28 17:04
- Tmax, drop-outs (EMA) Helmut 2012-03-28 17:49
- Tmax, drop-outs (EMA) pash413 2012-03-28 17:04
- Tmax, drop-outs (EMA) Helmut 2012-03-28 16:27
- Measuring impurities of the inactive ion of the API in BE? pharmino 2012-03-23 15:25
- Measuring impurities of the inactive ion of the API in BE? Dr_Dan 2012-03-26 11:14
- Dose Proportionality Ben 2012-03-25 20:18
